Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial

…, H Honda, RA Fowler, JS Lazar, G Shi… - The Lancet …, 2021 - thelancet.com
Background Elevated proinflammatory cytokines are associated with greater COVID-19 severity.
We aimed to assess safety and efficacy of sarilumab, an interleukin-6 receptor inhibitor, …

[HTML][HTML] Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials

…, GD Yancopoulos, DM Weinreich, S Wang, G Shi… - Nature medicine, 2023 - nature.com
Prurigo nodularis (PN) is a chronic inflammatory skin disease with intensely pruritic nodules.
The LIBERTY-PN PRIME and PRIME2 phase 3 trials enrolled adults with PN with ≥20 …

Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia

…, MN Vissers, MD Trip, C Gagné, G Shi… - Journal of the American …, 2008 - jacc.org
Objectives : The study evaluated the efficacy and safety of long-term coadministration of
ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia (…

Association between KRAS codon 13 mutations and clinical response to anti-EGFR treatment in patients with metastatic colorectal cancer: results from a meta …

J Chen, Y Ye, H Sun, G Shi - Cancer chemotherapy and pharmacology, 2013 - Springer
Purpose To comparatively evaluate whether metastatic colorectal cancer (mCRC) patients
with KRAS codon 13 mutations (codon 13 muts) can benefit from anti-EGFR treatment. …

XRCC1 Arg399Gln and clinical outcome of platinum-based treatment for advanced non-small cell lung cancer: a meta-analysis in 17 studies

J Chen, Q Zhao, G Shi, L Wang - Journal of Zhejiang University SCIENCE …, 2012 - Springer
Objective XRCC1 polymorphism is a research hotpot in individual treatment for non-small
cell lung cancer (NSCLC). To obtain the association between XRCC1 polymorphism and …

Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial

FX Lescure, H Honda, RA Fowler, JS Lazar, G Shi… - MedRxiv, 2021 - medrxiv.org
Background Elevated proinflammatory cytokines have been associated with 2019 coronavirus
disease (COVID-19) severity. We assessed efficacy and safety of sarilumab, an interleukin…

[HTML][HTML] Chemosensitivity of radioresistant cells in the multicellular spheroids of A549 lung adenocarcinoma

D Shi, G Shi, G Huang, J Zhang, E Lartigau - Journal of Experimental & …, 2009 - Springer
Background The relapse of cancer after radiotherapy is a clinical knotty problem. Previous
studies have demonstrated that the elevation of several factors is likely in some way to lead to …

Combination chemotherapy with paclitaxel, cisplatin and fluorouracil for patients with advanced and metastatic gastric or esophagogastric junction adenocarcinoma: a …

…, FC Zhang, XZ Ma, JJ Huang, L Chen, GM Shi… - Chinese Journal of …, 2012 - Springer
Objective To evaluate the efficacy and toxicity of the combination regimen of paclitaxel, cisplatin
and 5-FU (PCF) as first-line or second-line therapy in patients with advanced gastric and …

344 Dupilumab significantly improves itch and skin lesions in patients with prurigo nodularis: pooled results from two phase 3 trials (LIBERTY-PN PRIME and PRIME2)

…, E Mortensen, J Maloney, G Shi… - British Journal of …, 2023 - academic.oup.com
Prurigo nodularis (PN), a chronic inflammatory and pruritic skin condition with severely itchy
skin nodules, substantially affects the quality of life and is often inadequately controlled with …

510-Dupilumab is efficacious in patients with prurigo nodularis regardless of stable use of topical corticosteroids and topical calcineurin inhibitors: pooled results from …

…, S Ständer, N Mollanazar, G Shi… - British Journal of …, 2024 - academic.oup.com
Introduction Prurigo nodularis (PN) is a chronic inflammatory skin condition characterized
by severely itchy skin nodules, which substantially affects quality of life. Although topical …